Select a medication above to begin.
Tepylute
thiotepa
Black Box Warnings .
Myelosuppression
severe myelosuppression may occur; myeloablation with infection or bleeding may occur at high doses; monitor hematologic lab parameters
Potential for Carcinogenicity
potentially carcinogenic in humans
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments
breast CA
- [0.3-0.4 mg/kg/dose IV q1-4wk]
ovarian CA
- [0.3-0.4 mg/kg/dose IV q1-4wk]
renal dosing
- [see below]
- CrCl >60: no adjustment; CrCl <60: not defined, caution advised
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin >1.5x ULN: not defined, caution advised
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.